# EDGAR Filing Document

**Accession Number:** 0001840563
**File Stem:** 0001213900-26-014545
**Filing Date:** 2026-2
**Character Count:** 9448
**Document Hash:** f13e3b77391802614c8901928d9e4f25
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-014545.hdr.sgml**: 20260210

**ACCESSION NUMBER**: 0001213900-26-014545

**CONFORMED SUBMISSION TYPE**: 3/A

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20231113

**FILED AS OF DATE**: 20260210

**DATE AS OF CHANGE**: 20260210

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Parry Jeffrey
- **CENTRAL INDEX KEY:** 0002004493

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41875
- **FILM NUMBER:** 26618150

**MAIL ADDRESS:**
- **STREET 1:** 120 NEWPORT CENTER DRIVE, STE. 250
- **CITY:** NEWPORT BEACH
- **STATE:** CA
- **ZIP:** 92660
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PMGC Holdings Inc.
- **CENTRAL INDEX KEY:** 0001840563
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 851399981
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 675 WEST HASTINGS STREET
- **STREET 2:** SUITE 805
- **CITY:** VANCOUVER
- **PROVINCE COUNTRY:** A1
- **ZIP:** V6B1N2
- **BUSINESS PHONE:** 888-445-4886

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 675 WEST HASTINGS STREET
- **STREET 2:** SUITE 805
- **CITY:** VANCOUVER
- **PROVINCE COUNTRY:** A1
- **ZIP:** V6B1N2

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Elevai Labs Inc.
- **DATE OF NAME CHANGE:** 20211207

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Reactive Medical Labs Inc.
- **DATE OF NAME CHANGE:** 20210114

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3/A

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Parry Jeffrey<br><sub>(Last) (First) (Middle)</sub><br>675 WEST HASTINGS STREET<br>SUITE 805<br><sub>(Street)</sub><br>VANCOUVER, A1 V6B1N2<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2023-11-13 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>PMGC Holdings Inc. [ ELAB ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock |  |  |  |  |  |  |  | 3<sup>(1)</sup> | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Options to Purchase Common Stock<sup>(2)</sup> | 26264<sup>(5)</sup> |  |  |  |  |  |  | 2022-09-30<sup>(3)</sup> | 2032-09-30<sup>(3)</sup> | Common Stock | 1<sup>(4)</sup> |  |  | D |  |
| Options to Purchase Common Stock | 98000<sup>(8)</sup> |  |  |  |  |  |  | 2022-09-30<sup>(6)</sup> | 2032-09-30<sup>(6)</sup> | Common Stock | 4<sup>(7)</sup> |  |  | D |  |

---

### Footnotes:

(1) Reflects amount of shares of common stock of PMGC Holdings Inc. ("Company"), par value $0.0001 per share, on a post-reverse stock split basis (1-for-200 reverse stock split in November 2024, 1-for-7 reverse stock split in March 2025, 1-for-3.5 reverse stock split in September 2025, and 1-for-4 reverse stock split in January 2026; such reverse stock splits, collectively, "Splits"). The amount on a pre-Split basis (41,667) was reported in Jeffrey Parry's Form 3, filed with the U.S. Securities and Exchange Commission on January 17, 2024. The shares in this row represent shares outstanding following Mr. Parry's exercise of the options previously issued to him on August 16, 2021, under the Company's 2020 Equity Incentive Plan, in consideration for Mr. Parry's services to the Company. The 2020 Equity Incentive Plan was subsequently superseded by the Company's 2025 Equity Incentive Plan on September 15, 2025. Mr. Parry fully exercised such options on December 16, 2022.

(2) These are options previously issued to Mr. Parry on September 30, 2022, in consideration for Mr. Parry's services to the Company, under the Company's 2020 Equity Incentive Plan. The 2020 Equity Incentive Plan was subsequently superseded by the Company's 2025 Equity Incentive Plan. Vesting schedule is as follows: 25% of the underlying shares initially after 1 year, and remainder monthly over 36 months.

(3) Vesting schedule is as follows: 25% of the underlying shares initially after one (1) year, and the remainder over the course of 36 months.

(4) Reflects amount of shares underlying the options issued to Mr. Parry on a post-reverse stock split basis, following the Splits. The options were issued to Mr. Parry on September 30, 2022 as consideration for Mr. Parry's services to the Company, under the Company's 2020 Equity Incentive Plan. The 2020 Equity Incentive Plan was subsequently superseded by the Company's 2025 Equity Incentive Plan. On a pre-Split basis, the amount underlying the options was 16,000.

(5) Reflects exercise price of the underlying shares on a post-reverse stock split basis, following the Splits. The options were issued to Mr. Parry on September 30, 2022 under the Company's 2020 Equity Incentive Plan, as consideration for Mr. Parry's services to the Company. The 2020 Equity Incentive Plan was subsequently superseded by the Company's 2025 Equity Incentive Plan on September 15, 2025.

(6) Vesting schedule is as follows: 25% of the underlying shares initially after one (1) year, and the remainder over the course of 36 months.

(7) Reflects amount of shares underlying the options issued to Mr. Parry on a post-reverse stock split basis, following the Splits. The options were issued to Mr. Parry on September 30, 2022, as consideration for Mr. Parry's services to the Company, under the 2020 Equity Incentive Plan. On a pre-Split basis, the amount underlying the options was 80,000.

(8) Reflects exercise price of the underlying shares on a post-reverse stock split basis, following the Splits. The options were issued to Mr. Parry as consideration for his services to the Company on September 30, 2022, under the 2020 Equity Incentive Plan. The 2020 Equity Incentive Plan was subsequently superseded by the Company's 2025 Equity Incentive Plan on September 15, 2025.

**Signature:** /s/ Jeffrey Parry  
**Date:** 2026-02-10

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**